How to Switch Patients to Biosimilars

Roy M Fleischman, MD: The other point you raised was that if a patient does not respond to the branded product adalimumab, would you expect them to respond to the biosimilar? I agree with you. Why should they? They don’t. The probability that this is not the case is probably 98%. Why take that 2% …

How to Switch Patients to Biosimilars Read More »